Digital Display Labels are a groundbreaking new approach for clinical trials. They enable flexible, digital marking of investigational drugs and have the potential to replace conventional labels in the future, eliminating the need for time-consuming re-labeling. This not only optimizes the supply chain but also accelerates the entire trial process and enhances efficiency in providing current information for patients and clinical personnel. Schreiner MediPharm has developed a new concept for this purpose.

Clinical trials demand utmost flexibility, speed, and precision but conventional labels with static information reach their limits in that regard. Changes in the patient group, the expiration date, or the protocol number as well as regulatory adjustments require complex re-labeling of the investigational drugs, which causes delays and high costs.

The Digital Display Label from Schreiner MediPharm is an electronic component with an e-label indicator. The solution is based on a modular, reusable plastic housing securely enclosing the display electronics. An adapter system enables the Digital Display Label to be connected to the respective packaging form. Thus, the label is suitable for flat applications like blister wallets or kit boxes and for round applications such as plastic bottles or vials. The latter can additionally be equipped with light protection or a blinding feature. The e-label content can be updated in real time so that patients and clinical personnel receive the information in a timely manner.

In addition to flexibility, the Digital Display Label scores with sustainability and reliability. Both the housing and the container adapter are reusable, which saves resources and avoids waste. The integrated electronics are protected against external influences and the adapter ensures a reliable connection between the Digital Display Label and the container or the packaging. Existing standard packaging can be used for integrating the Digital Display Label without any modifications.

Thanks to digital updating of the label information, delays due to manual re-labeling are eliminated, inventory levels are reduced, and the entire logistics process is optimized. At the same time, patient compliance increases and the risk of potential trial discontinuations due to label changes clearly decreases. Enhanced efficiency not only shortens time to market but also leads to significant cost savings for research-based pharmaceutical companies.